Peroxisome proliferator-activated receptor delta and cardiovascular disease

被引:31
|
作者
Ehrenborg, Ewa [1 ]
Skogsberg, Josefin [2 ]
机构
[1] Karolinska Inst, Atherosclerosis Res Unit, Karolinska Univ Hosp, Dept Med,Ctr Mol Med, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Cardiovasc Genom Grp, Vasc Biol Unit, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
Peroxisome proliferator-activated receptor delta; Cardiovascular disease; Risk factors; Mouse models; Agonist; Single nucleotide polymorphism; LOW-DENSITY LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; CORONARY-ARTERY-DISEASE; NF-KAPPA-B; PPAR-DELTA; INSULIN-RESISTANCE; ENDOTHELIAL-CELLS; METABOLIC SYNDROME; SKELETAL-MUSCLE; INFLAMMATORY RESPONSE;
D O I
10.1016/j.atherosclerosis.2013.08.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent reports have shown that peroxisome proliferator-activated receptor delta (PPARD) plays an important role in different vascular processes suggesting that PPARD is a significant modulator of cardiovascular disease. This review will focus on PPARD in relation to cardiovascular risk factors based on cell, animal and human data. Mouse studies suggest that PPARD is an important metabolic modulator that may have implications for cardiovascular disease (CVD). Specific human PPARD gene variants show no clear association with CVD but interactions between variants and lifestyle factors might influence disease risk. During recent years, development of specific and potent PPARD agonists has also made it possible to study the effects of PPARD activation in humans. PPARD agonists seem to exert beneficial effects on dyslipidemia and insulin-resistant syndromes but safety issues have been raised due to the role that PPARD plays in cell proliferation. Thus, large long term outcome as well as detailed safety and tolerability studies are needed to evaluate whether PPARD agonists could be used to treat CVD in humans. (c) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:95 / 106
页数:12
相关论文
共 50 条
  • [1] Roles of peroxisome proliferator-activated receptor γ in cardiovascular disease
    Takano, H
    Komuro, I
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2002, 16 (01) : 108 - 114
  • [2] Peroxisome proliferator-activated receptor γ:: Implications for cardiovascular disease
    Hsueh, WA
    Bruemmer, D
    [J]. HYPERTENSION, 2004, 43 (02) : 297 - 305
  • [3] Peroxisome Proliferator-Activated Receptor γ and Cardiovascular Diseases
    Takano, Hiroyuki
    Komuro, Issei
    [J]. CIRCULATION JOURNAL, 2009, 73 (02) : 214 - 220
  • [4] Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
    Fuior, Elena Valeria
    Zvintzou, Evangelia
    Filippatos, Theodosios
    Giannatou, Katerina
    Mparnia, Victoria
    Simionescu, Maya
    Gafencu, Anca Violeta
    Kypreos, Kyriakos E.
    [J]. BIOMEDICINES, 2023, 11 (10)
  • [5] Peroxisome proliferator-activated receptor γ and metabolic disease
    Willson, TM
    Lambert, MH
    Kliewer, SA
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 : 341 - 367
  • [6] The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
    Friedland, Sayuri N.
    Leong, Aaron
    Filion, Kristian B.
    Genest, Jacques
    Lega, Iliana C.
    Mottillo, Salvatore
    Poirier, Paul
    Reoch, Jennifer
    Eisenberg, Mark J.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2012, 125 (02): : 126 - 133
  • [7] The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
    Kolatkar, Nikheel S.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2013, 126 (03): : E11 - E11
  • [8] Association of peroxisome proliferator-activated receptor delta and additional gene-smoking interaction on cardiovascular disease
    Yang, Wenqi
    Mao, Shudan
    Qu, Baoze
    Zhang, Fengxiang
    Xu, Zhaolong
    [J]. CLINICAL AND EXPERIMENTAL HYPERTENSION, 2017, 39 (02) : 114 - 118
  • [9] Interaction between peroxisome proliferator-activated receptor gamma and smoking on cardiovascular disease
    Ding, Xiang
    Wang, Rong
    Liu, Li
    Yu, Qiushi
    Wang, Zhiquan
    Ma, Zhiqiang
    Zhu, Qiming
    [J]. PHYSIOLOGY & BEHAVIOR, 2016, 153 : 28 - 32
  • [10] Peroxisome Proliferator-Activated Receptor α and Hypertensive Heart Disease
    María J. Goikoetxea
    Javier Beaumont
    Javier Dr Díez
    [J]. Drugs, 2004, 64 : 9 - 18